Dr. McGregor on Immunotherapy Combinations in Kidney Cancer

Video

In Partnership With:

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses combinations of immunotherapy for patients with kidney cancer.

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses combinations of immunotherapy for patients with kidney cancer.

Two phase III trials that are investigating immunotherapy combinations are CheckMate-214 and IMmotion151. CheckMate-214 investigated nivolumab (Opdivo) and ipilimumab (Yervoy), whereas IMmotion151 investigated atezolizumab (Tecentriq) and bevacizumab (Avastin). The CheckMate-214 study saw impressive complete response (CR) rates of 16% for patients with PD-L1 expression.

IMmotion151 also had a CR rate of 9%. The most appealing aspect of that trial was the low toxicity profile. In CheckMate-214, it seemed to only work best for intermediate- and poor-risk patients, says McGregor. But, in the IMmotion151 study, there was a benefit across all subgroups, independent of risk status.

There are multiple ongoing phase III trials inspired by phase I data that showed impressive response rates. The hope is that those response rates translate into the phase III trials and improve CR rates.

Related Videos
Don S. Dizon, MD
Rohan Garje, MD
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP